Calcium-channel blocking agents verapamil and diltiazem are inhibitors of vasopressin-induced human platelet activation.
1. This study investigated the influences of calcium-channel blocking agents verapamil and diltiazem on platelet responses induced by arginine vasopressin (AVP) and lysine vasopressin (LVP). 2. The substances inhibited platelet aggregation induced by both low and high AVP concentrations, LVP and adrenaline plus AVP. IC50 values of each drug are lower than those determined for ADP- and collagen-elicited aggregation. Verapamil and diltiazem also decreased AVP-induced thromboxane B2 synthesis. 3. Other series of experiments showed that the addition of ethyleneglycol-bis-(beta-amino-ethyl ether) N, N'-tetra-acetic acid to platelet-rich plasma samples also prevented the platelet response to vasopressin polypeptides. 4. Our data provide evidence that the effects of verapamil and diltiazem on vasopressin-induced platelet responses may be directly related to inhibition of extracellular calcium entry.
Anfossi
G
G
Department of Clinical and Biological Sciences, University of Turin, Ospedale S. Luigi Gonzaga, Orbassano, Torino, Italy.
Mularoni
E
E
Massucco
P
P
Cavalot
F
F
Burzacca
S
S
Mattiello
L
L
Trovati
M
M
D000328:Adult; D001127:Arginine Vasopressin / Q000494:pharmacology; D004110:Diltiazem / Q000494:pharmacology*; D004533:Egtazic Acid / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D008236:Lypressin / Q000494:pharmacology; D008297:Male; D015539:Platelet Activation / Q000187:drug effects*; D013929:Thromboxane B2 / Q000096:biosynthesis; D014667:Vasopressins / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D014700:Verapamil / Q000494:pharmacology*
D014667:Vasopressins; D001127:Arginine Vasopressin; D008236:Lypressin; D004533:Egtazic Acid; D013929:Thromboxane B2; D014700:Verapamil; D004110:Diltiazem